ARPA-H selects Tempus as contract research organization for ADAPT Program

AI in action: MANAscore tool moves closer to clinic

One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.

June 05, 2026

Vol.52 No.22

In Brief

Advocate Health partners with AI startup to connect more cancer patients to clinical trials

Advocate Health and Lind, an AI-powered clinical reserch platform, are partnering to help connect more cancer patients to clinical trials.

June 05, 2026

Vol.52 No.22

In Brief

OpenEvidence integrates ASCO guidelines, figures, and flowcharts into specialty oncology model

OpenEvidence announced an integration of ASCO Guidelines, figures, and flowcharts into the OpenEvidence model.

June 05, 2026

Vol.52 No.22

In Brief

UCLA researchers awarded $3.2M NIH grant to develop AI tool for more personalized liver cancer treatment

Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.

June 05, 2026

Vol.52 No.22

Clinical Roundup

AI model links tumor mutations to treatment response, UCSD study finds

An artificial intelligence model may be able to translate a tumor’s complex genetic profile into predictions about how that cancer may respond to treatment, according to a study conducted by researchers at University of California San Diego.

May 29, 2026

Vol.52 No.21

Clinical Roundup

Cedars-Sinai leads development of AI-based tool to predict spatial gene expression in tumors

A team led by Cedars-Sinai Health Sciences University investigators has created a faster, cheaper way to determine the genes expressed in cancerous tumors. The AI-based tool could make personalized cancer treatment available to more patients.

May 15, 2026

Vol.52 No.19

ARPA-H selects Tempus as contract research organization for ADAPT Program

YOU MAY BE INTERESTED IN

AI in action: MANAscore tool moves closer to clinic

Advocate Health partners with AI startup to connect more cancer patients to clinical trials

OpenEvidence integrates ASCO guidelines, figures, and flowcharts into specialty oncology model

UCLA researchers awarded $3.2M NIH grant to develop AI tool for more personalized liver cancer treatment

AI model links tumor mutations to treatment response, UCSD study finds

Cedars-Sinai leads development of AI-based tool to predict spatial gene expression in tumors

Renew today!

Subscriber content

Never miss an issue!

Login